Points to Consider for Clinical Efficacy Evaluation of Drugs for Palmoplantar Pustulosis — PMDA Early Consideration Summary
Points to Consider for Clinical Development of Drugs Intended for Treatment of Psoriatic Arthritis — PMDA Early Consideration Summary
Points to Consider for Clinical Development of Drugs Intended for Treatment of Antimicrobial-resistant Gram-negative Bacterial Infections — PMDA Early Consideration Summary
Information Regarding Explanations to Driver Mutations in the Development of Anti-cancer Drugs — PMDA Early Consideration Summary
Considerations for the Clinical Evaluation of Blood Coagulation Factor VIII and Factor IX Products for Pediatric Congenital Hemophilia — PMDA Early Consideration Summary
Considerations for clinical development of intravenous formulations containing the same active ingredient as oral products for patients who are temporarily unable to receive oral administration in epilepsy treatment — PMDA Early Consideration Summary
Consideration in the development of drugs for hypertrophic cardiomyopathy — PMDA Early Consideration Summary
Consideration in the development of drugs for pulmonary arterial hypertension — PMDA Early Consideration Summary